Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)

Toxicology and Applied Pharmacology

Volumn 230, Issue 1, 2008, Pages 117-125

  Fonsart, Julien ^a,b,c   Menet, Marie Claude ^a   Declèves, Xavier ^a,b,c   Galons, Hervé ^a,c   Crété, Dominique ^a,b,c   Debray, Marcel ^a,b,c   Scherrmann, Jean Michel ^a,b,c   Noble, Florence ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CNRS   (France)

^c INSERM   (France)

Author keywords

Acute toxicity; Ecstasy; Gender; MDA; MDMA; Metabolism; Sex

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CHEMICAL STRUCTURE; CONTROLLED STUDY; DEMETHYLATION; ENZYME ACTIVITY; FEMALE; HYPOTHERMIA; LD 50; LETHALITY; LIVER METABOLISM; LIVER MICROSOME; MALE; NONHUMAN; RAT; RECTUM TEMPERATURE; SEX DIFFERENCE; THERMOREGULATION;

ANIMALS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALLUCINOGENS; LETHAL DOSE 50; MALE; METHYLATION; MICROSOMES, LIVER; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEX CHARACTERISTICS;

RATTUS; RODENTIA;

EID: 44649189106     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.02.004     Document Type: Article

References (43)

1. Bai F., Jones D.C., Lau S.S., and Monks T.J. Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase. Chem. Res. Toxicol. 14 (2001) 863-870
2. Beck F., and Legleye S. Usages de drogues et contextes d'usage entre 17 et 19 ans, évolutions récentes. In ESCAPAD 2002 (2003), OFDT, Paris
3. Becker J.B., Molenda H., and Hummer D.L. Gender differences in the behavioral responses to cocaine and amphetamine Implications for mechanisms mediating gender differences in drug abuse. Ann. N. Y. Acad. Sci. 937 (2001) 172-187
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
5. Burke M.D., Thompson S., Elcombe C.R., Halpert J., Haaparanta T., and Mayer R.T. Ethoxy-, pentoxy-and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34 (1985) 3337-3345
6. Cadet J.L., Ladenheim B., Baum I., Carlson E., and Epstein C. CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res. 655 (1994) 259-262
7. Capela J.P., Macedo C., Branco P.S., Ferreira L.M., Lobo A.M., Fernandes E., Remiao F., Bastos M.L., Dirnagl U., Meisel A., and Carvalho F. Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 146 (2007) 1743-1757
8. Carroll M.E., Lynch W.J., Roth M.E., Morgan A.D., and Cosgrove K.P. Sex and estrogen influence drug abuse. Trends Pharmacol. Sci. 25 (2004) 273-279
9. Cho A.K., Hiramatsu M., Distefano E.W., Chang A.S., and Jenden D.J. Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis. Drug. Metab. Dispos. 18 (1990) 686-691
10. Chu T., Kumagai Y., DiStefano E.W., and Cho A.K. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem. Pharmacol. 51 (1996) 789-796
11. Colado M.I., Williams J.L., and Green A.R. The hyperthermic and neurotoxic effects of "Ecstasy" (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol. 115 (1995) 1281-1289
12. Dafters R.I. Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats. Psychopharmacology (Berl) 114 (1994) 505-508
13. Dafters R.I. Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol. Behav. 58 (1995) 877-882
14. de la Torre R., Farre M., Roset P.N., Pizarro N., Abanades S., Segura M., Segura J., and Cami J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug. Monit. 26 (2004) 137-144
15. De Souza I., Kelly J.P., Harkin A.J., and Leonard B.E. An appraisal of the pharmacological and toxicological effects of a single oral administration of 3,4-methylenedioxymethamphetamine (MDMA) in the rat. Pharmacol. Toxicol. 80 (1997) 207-210
16. Delaforge M., Jaouen M., and Bouille G. Inhibitory metabolite complex formation of methylendioxymethamphetamine with rat and human cytochromes P450. Particular involvement of CYP2D. Environ. Toxicol. Pharmacol. 7 (1999) 153-158
17. Dowling G.P., McDonough III E.T., and Bost R.O. 'Eve' and 'Ecstasy' A report of five deaths associated with the use of MDEA and MDMA. JAMA 257 (1987) 1615-1617
18. Fitzgerald R.L., Blanke R.V., Rosecrans J.A., and Glennon R.A. Stereochemistry of the metabolism of MDMA to MDA. Life Sci. 45 (1989) 295-301
19. Fitzgerald R.L., Blanke R.V., and Poklis A. Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. Chirality 2 (1990) 241-248
20. Gordon C.J., Watkinson W.P., O'Callaghan J.P., and Miller D.B. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol. Biochem. Behav. 38 (1991) 339-344
21. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55 (2003) 463-508
22. Hardman H.F., Haavik C.O., and Seevers M.H. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol. Appl. Pharmacol. 25 (1973) 299-309
23. Horbach G.J., Van Asten J.G., Rietjens I.M., Kremers P., and Van Bezooijen C.F. The effect of age on inducibility of various types of rat liver cytochrome P-450. Xenobiotica 22 (1992) 515-522
24. Jackson K.L., Walker E.L., and Pace N. Centrifugal preparation of rat liver mitochondria free of microsomes. Science 118 (1953) 136-137
25. Jones D.C., Duvauchelle C., Ikegami A., Olsen C.M., Lau S.S., de la Torre R., and Monks T.J. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J. Pharmacol. Exp. Ther. 313 (2005) 422-431
26. Koenig J., Lazarus C., Jeltsch H., Ben Hamida S., Riegert C., Kelche C., Jones B.C., and Cassel J.C. MDMA (ecstasy) effects in pubescent rats: males are more sensitive than females. Pharmacol. Biochem. Behav. 81 (2005) 635-644
27. Kumagai Y., Wickham K.A., Schmitz D.A., and Cho A.K. Metabolism of methylenedioxyphenyl compounds by rabbit liver preparations Participation of different cytochrome P450 isozymes in the demethylenation reaction. Biochem. Pharmacol. 42 (1991) 1061-1067
28. Liechti M.E., Gamma A., and Vollenweider F.X. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 154 (2001) 161-168
29. Lim H.K., and Foltz R.L. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem. Res. Toxicol. 1 (1988) 370-378
30. Litchfield J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. 96 (1949) 99-113
31. Malpass A., White J.M., Irvine R.J., Somogyi A.A., and Bochner F. Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. Pharmacol. Biochem. Behav. 64 (1999) 29-34
32. Maurer, H.H., Bickeboeller-Friedrich, J., Kraemer, T., Peters, F.T., 2000. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol. Lett. 112-113, 133-142.
33. McCann U.D., Slate S.O., and Ricaurte G.A. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'). Drug. Safety 15 (1996) 107-115
34. McKenna C. Ecstasy is low in league table of major causes of deaths. BNJ 325 (2002) 296
35. Mechan A., Yuan J., Hatzidimitriou G., Irvine R.J., McCann U.D., and Ricaurte G.A. Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31 (2006) 339-350
36. Milhazes N., Cunha-Oliveira T., Martins P., Garrido J., Oliveira C., Rego A.C., and Borges F. Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine ("ecstasy") and its metabolites on undifferentiated PC12 cells: a putative structure-toxicity relationship. Chem. Res. Toxicol. 19 (2006) 1294-1304
37. NIDA. Monitoring the future. national survey results on drug use, 1975-2001. vol. I: secondary school students (2002), U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, MD
38. Onderwater R.C., Venhorst J., Commandeur J.N., and Vermeulen N.P. Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening. Chem. Res. Toxicol. 12 (1999) 555-559
39. Peroutka S.J. Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. N. Engl. J. Med. 317 (1987) 1542-1543
40. Schifano F. A bitter pill Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl) 173 (2004) 242-248
41. Segura M., Ortuno J., Farre M., McLure J.A., Pujadas M., Pizarro N., Llebaria A., Joglar J., Roset P.N., Segura J., and de La Torre R. 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem. Res. Toxicol. 14 (2001) 1203-1208
42. Simon N.G., and Mattick R.P. The impact of regular ecstasy use on memory function. Addiction 97 (2002) 1523-1529
43. Winstock A.R., Wolff K., and Ramsey J. Ecstasy pill testing: harm minimization gone too far?. Addiction 96 (2001) 1139-1148